So far, it is suspected that systemic administration of TrkB agonists can lead to anorexia and weight loss, and systemic therapy with nerve growth factor (NGF) has been shown to evoke myalgias and arthralgias [50,51]. The gene discussed is NGF; the disease is Anorexia.